Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Osteoporotic vertebral fracture (OVF) is the most common type of osteoporotic fracture and is associated with immobility and mortality. Bone anabolic agents, such as abaloparatide (ABL), are usually administered to patients with OVF to prevent subsequent fractures. Although several studies have shown that bone anabolic agents promote healing of long bone fractures, there is little evidence of their healing effect on vertebral bone fractures. In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF. Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery. We found that ABL significantly increased bone mineral content and improved trabecular structural parameters at the vertebral defect site. Moreover, ABL significantly increased bone strength of the defected vertebrae. Bone histochemical analysis revealed formation of thick trabecular bone networks at the defect site after ABL administration, consistent with an improvement in trabecular structural parameters by ABL. ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site. On the other hand, ABL did not affect the number of cathepsin K-positive osteoclasts per bone surface, suggesting that ABL did not promote excessive bone resorption. Our findings suggest that ABL is useful not only for preventing secondary vertebral fractures but also for promoting bone healing in OVF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:182 |
|---|---|
| Enthalten in: |
Bone - 182(2024) vom: 26. Apr., Seite 117056 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Makino, Akito [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AVK0I6HY2U |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bone.2024.117056 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368928942 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368928942 | ||
| 003 | DE-627 | ||
| 005 | 20240401232651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bone.2024.117056 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM368928942 | ||
| 035 | |a (NLM)38402920 | ||
| 035 | |a (PII)S8756-3282(24)00045-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Makino, Akito |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Osteoporotic vertebral fracture (OVF) is the most common type of osteoporotic fracture and is associated with immobility and mortality. Bone anabolic agents, such as abaloparatide (ABL), are usually administered to patients with OVF to prevent subsequent fractures. Although several studies have shown that bone anabolic agents promote healing of long bone fractures, there is little evidence of their healing effect on vertebral bone fractures. In the present study, we investigated the effect of ABL on vertebral bone defects using ovariectomized (OVX) rats with vertebral body drill-hole defects, an animal model of OVF. Eight-week-old female Sprague-Dawley rats were subjected to OVX, followed by the 32-36 days of bone depletion period, once-daily subcutaneous ABL was administered to OVX rats at a dose of 30 μg/kg for a maximum of 6 weeks from the day of the vertebral defect surgery. We found that ABL significantly increased bone mineral content and improved trabecular structural parameters at the vertebral defect site. Moreover, ABL significantly increased bone strength of the defected vertebrae. Bone histochemical analysis revealed formation of thick trabecular bone networks at the defect site after ABL administration, consistent with an improvement in trabecular structural parameters by ABL. ABL increased ALPase- and PHOSPHO1-positive osteoblastic cells and ALPase/PCNA double-positive cells, indicating enhanced preosteoblast proliferation as well as bone formation at the defect site. On the other hand, ABL did not affect the number of cathepsin K-positive osteoclasts per bone surface, suggesting that ABL did not promote excessive bone resorption. Our findings suggest that ABL is useful not only for preventing secondary vertebral fractures but also for promoting bone healing in OVF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abaloparatide | |
| 650 | 4 | |a Animal model | |
| 650 | 4 | |a Bone formation | |
| 650 | 4 | |a Fracture healing | |
| 650 | 4 | |a OVF | |
| 650 | 7 | |a abaloparatide |2 NLM | |
| 650 | 7 | |a AVK0I6HY2U |2 NLM | |
| 650 | 7 | |a Anabolic Agents |2 NLM | |
| 650 | 7 | |a Parathyroid Hormone-Related Protein |2 NLM | |
| 700 | 1 | |a Hasegawa, Tomoka |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Tomomaya |e verfasserin |4 aut | |
| 700 | 1 | |a Takagi, Hideko |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Yoshimasa |e verfasserin |4 aut | |
| 700 | 1 | |a Miyakoshi, Naohisa |e verfasserin |4 aut | |
| 700 | 1 | |a Amizuka, Norio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone |d 1992 |g 182(2024) vom: 26. Apr., Seite 117056 |w (DE-627)NLM01297238X |x 1873-2763 |7 nnns |
| 773 | 1 | 8 | |g volume:182 |g year:2024 |g day:26 |g month:04 |g pages:117056 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bone.2024.117056 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 182 |j 2024 |b 26 |c 04 |h 117056 | ||